# MARKER THERAPEUTICS, INC.: Safety and Efficacy of a Multi-Tumor-Associated Antigen-Specific T Cell Therapy in Pancreatic Cancer Patients

**Lab Budget Score:** 55/100

| Field | Value |
|---|---|
| Organization | MARKER THERAPEUTICS, INC. |
| Location | HOUSTON, TX |
| Project | Safety and Efficacy of a Multi-Tumor-Associated Antigen-Specific T Cell Therapy in Pancreatic Cancer Patients |
| Project number | 1R01FD008756-01 |
| Mechanism | R01 |
| Institute | Food and Drug Administration |
| Award | $645,493 |
| Awarded | 2026-09-24 |
| Project period | 2026-09-25 to 2030-08-31 |
| UEI | CK3KR85CSP23 |

## Why this score
- Award of $400K or more.
- Research or center grant: supplies, instruments and services budget.

Source: NIH RePORTER (newly awarded projects) (https://reporter.nih.gov/project-details/11444174). Last refreshed: 2026-11-03T18:16:24.961Z.
Award data comes from NIH RePORTER and may be revised by NIH. Organization-level only; investigator names and contacts are not included. Informational only.